{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:02:23Z","timestamp":1785150143544,"version":"3.55.0"},"reference-count":35,"publisher":"Academy of Managed Care Pharmacy","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.18553\/jmcp.2026.32.8.968","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:00Z","timestamp":1785148860000},"page":"968-978","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars"],"prefix":"10.18553","volume":"32","author":[{"given":"Aaron B.","family":"Mendelsohn","sequence":"first","affiliation":[{"name":"Biologics and Biosimilars Collective Intelligence Consortium and Academy of Managed Care Pharmacy Research Institute, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese A.","family":"DeFor","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba","family":"Audrey Djibo","sequence":"additional","affiliation":[{"name":"CVS Health, Blue Bell, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Myers","sequence":"additional","affiliation":[{"name":"PearlDiver Technologies Inc, Colorado Springs, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamala A.","family":"Pawloski","sequence":"additional","affiliation":[{"name":"Biologics and Biosimilars Collective Intelligence Consortium and Academy of Managed Care Pharmacy Research Institute, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Biologics and Biosimilars Collective Intelligence Consortium and Academy of Managed Care Pharmacy Research Institute, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","unstructured":"Food and Drug Administration. Real-World Evidence. Accessed April 22, 2026. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.07.003"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2639"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819832661"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0135"},{"key":"r6","unstructured":"Biologics Price Competition and Innovation Act of 2009 (BPCIA). Pub. L. No. 111-148, \u00a7 7001, 124 Stat. 119, 804 (2010)."},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2542-1"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.06.016"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00446-7"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1889511"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01601-2"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.12.1234"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12676"},{"key":"r14","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Considerations in Demonstrating Interchangeability With a Reference Product: Update. Accessed May 18, 2025. https:\/\/www.fda.gov\/media\/179456\/download"},{"key":"r15","unstructured":"U.S. Food and Drug Administration. Framework for FDA\u2019s Real-World Evidence Program. 2018. Accessed July 13, 2025. https:\/\/www.fda.gov\/media\/120060\/download"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13904"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00708-w"},{"key":"r18","unstructured":"Mylan Pharmaceuticals IA. Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Subjects Receiving Humira\n                      \u00ae\n                      Pre Filled Syringe (40\u00a0mg) Continuously and Subjects Undergoing Repeated Switches Between Humira\n                      \u00ae\n                      Pre Filled Syringe (40\u00a0mg) and Hulio Pre-filled Syringe (40\u00a0mg). Accessed April 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05637515"},{"key":"r19","unstructured":"Amgen. A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Accessed April 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04761627"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.031"},{"key":"r21","unstructured":"Nichi-Iko Pharmaceutical Co., Ltd. A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE). Accessed April 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT02990806"},{"key":"r22","unstructured":"Biocad. Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis (BIORA). ClinicalTrials.gov. Accessed April 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT01759030"},{"key":"r23","unstructured":"Zhejiang Teruisi Pharmaceutical Inc. A Study Assessing the Interchangeability Between TRS003 and Bevacizumab\n                      \u00ae\n                      For Colorectal Cancer (CRC). ClinicalTrials.gov. Accessed April 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05378867"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.11.916"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"r26","unstructured":"Rand. 36-Item Short Form Survey (SF-36). Accessed April 17, 2025. https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form.html"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2187196"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.5811\/WESTJEM.58408"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02260-0"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0104"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.6352"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.124537"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000004071"},{"issue":"1","key":"r34","first-page":"32","volume":"19","author":"Holmes JH","year":"2021","journal-title":"Methods Inf Med"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5690"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:21Z","timestamp":1785148881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.8.968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.18553\/jmcp.2026.32.8.968"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.8.968","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}